Interstitial Lung Disease: A Year in Review

This text-based activity will focus on the benefits of early diagnosis and appropriate treatment modalities for managing patients with interstitial lung disease (ILD). It will educate clinicians on recognizing varied disease presentations, mechanisms associated with the disease, common complications and improved drug delivery methodologies. It includes images, charts and audio clips featuring faculty commentary.

Interstitial lung disease (ILD) represents a large, heterogeneous group of more than 200 different entities. Idiopathic pulmonary fibrosis and connective tissue disease-associated ILD account for the majority of cases and are associated with significant morbidity and mortality. Despite the availability of guidelines, patients report delays in receiving a diagnosis and initiation of therapy. A prompt, accurate diagnosis is needed to ensure use of appropriate therapy. This eNewsletter will update clinicians on new and emerging science in the field of ILD, including application of emerging agents into treatment plans.

Upon completion of this activity, participants will be able to:
•Outline the diagnostic workup and the role of the multidisciplinary team in ensuring an accurate diagnosis of ILD, including IPF and CTD-ILD
•Discuss available guidelines and approaches for the management of patients with IPF and CTD-ILD
•Review patient needs and considerations for improving the patient-physician dialogue